Data4Cure has announced an ongoing multi-year partnership with Pfizer, leveraging knowledge graph AI and advanced analytics to accelerate drug discovery and development. Through Data4Cure’s Biomedical Intelligence® Cloud platform, Pfizer integrates multi-omics data into a continuously updated knowledge graph, bridging public and proprietary datasets to extract actionable insights.
The collaboration, which will be highlighted at the Precision Medicine World Conference in February 2025, focuses on expanding AI-driven data integration across multiple disease areas. CEO Janusz Dutkowski emphasized that the partnership addresses a critical challenge in pharmaceutical research — transforming vast multimodal data into knowledge that reduces development time and costs while increasing success rates.
Pfizer’s Vice President of Discovery Technologies, Paul Rejto, underscored the company’s commitment to AI-driven research, stating that integrating diverse datasets into a unified knowledge graph allows scientists to compare results across studies, uncover disease mechanisms, and enhance drug response insights. The initiative aims to advance AI-powered drug discovery and support groundbreaking therapeutic breakthroughs.
